Helpdesk

Sales contact

Home > PRO

PRO

Article

Expanding investor confidence: The strategic value of Patient Reported Outcomes (PROs) in biotech fundraising

For biotech companies engaged in the clinical development of a therapeutic innovation, securing investor trust is as critical as demonstrating the scientific value of their molecule. One powerful yet underleveraged...

Article

Leveraging the potential of Patient Reported Outcome (PRO) data to accelerate therapeutic innovation market access

biotech market access PRO

Patients Reported Outcome (PRO) data provide information on patient health that is obtained directly from the patient.PRO measures serve to...

Webcast

The critical importance of Patient Reported Outcomes (PROs) for Emerging Biopharma Companies

biotech PRO

In today’s competitive landscape, biotech and emerging biopharma companies (EBPs) must demonstrate the value of their innovations early and convincingly....

Subscribe to our newsletter

Expanding investor confidence: The strategic value of Patient Reported Outcomes...

Leveraging the potential of Patient Reported Outcome (PRO) data to...

Gastrointestinal Tract Diseases Research: Moving Towards Patient-Centered Clinical Trials

The critical importance of Patient Reported Outcomes (PROs) for Emerging...

Turning experience into evidence: PROs in IBD clinical research

BYOD on the rise

About the author

Céline Hollinger

Celine brings almost two decades of communications experience in the life sciences. As a co-founder of a healthcare communication agency for over a decade, she has supported top pharma and innovative healthcare companies. Since April 2019, she has been leading marketing and communication at Kayentis with her innovative strategies.

Kayentis Europe
19 bis, chemin du vieux Chêne
38240 Meylan
France
Phone: +33 (0)4 76 00 54 20

Kayentis US
186 South Street
Suite 600
Boston, Massachusetts 02111
USA